Table 6.

Stratified analysis of factors associated with BALF positivity in pulmonary TB sputum-negative suspects and those without sputum

	BALF (+) n/N (%)	BALF (−) n/N (%)	P-value	OR (95% CI)
IGRA/Age			<0.001
IGRA (−)/> 35 year	30/239 (12.6)	209/239 (87.4)		Reference
IGRA (−)/≤ 35 year	34/192 (17.7)	158/192 (82.3)		1.499 (0.880–2.554)
IGRA (+)/> 35 year	55/212 (25.9)	157/212 (74.1)		2.441 (1.494–3.986)
IGRA(+)/≤ 35 year	146/295 (49.5)	149/295 (50.5)		6.826 (4.372–10.658)
Cavity/Age			<0.001
Cavity (−)/> 35 year	76/453 (17.0)	371/477 (83.0)		Reference
Cavity (−)/≤ 35 year	152/477 (31.9)	325/477 (68.1)		2.283 (1.669–3.122)
Cavity (+)/> 35 year	16/49 (32.7)	33/49 (67.3)		2.367 (1.240–4.516)
Cavity (+)/≤ 35 year	41/55 (74.5)	14/55 (25.5)		14.296 (7.426–27.521)
CD8/Age			<0.001
CD8> 500/> 35 year	16/82 (19.5)	66/82 (80.5)		Reference
CD8> 500/≤ 35 year	30/117 (25.6)	87/117 (74.4)		1.422 (0.716–2.824)
CD8 ≤ 500/> 35 year	49/222 (22.1)	173/222 (77.9)		1.168 (0.621–2.197)
CD8 ≤ 500/ ≤ 35 year	104/246 (42.3)	142/246 (57.7)		3.021 (1.655–5.515)
IGRA/Cavity/Age			<0.001
IGRA (−)/Cavity (−)/> 35 year	24/219 (11.0)	195/219 (89.0)		Reference
IGRA (−)/Cavity (−)/≤ 35 year	23/174 (13.2)	151/174 (86.8)		1.238 (0.672–2.278)
IGRA (−)/Cavity (+)/> 35 year	6/20 (30.0)	14/20 (70.0)		3.482 (1.223–9.912)
IGRA (−)/Cavity (+)/≤ 35 year	11/18 (61.1)	7/18 (38.9)		12.768 (4.521–36.056)
IGRA (+)/Cavity (−)/> 35 year	45/184 (24.5)	139/184 (75.5)		2.630 (1.531–4.519)
IGRA (+)/Cavity (−)/≤ 35 year	118/262 (45.0)	144/262 (55.0)		6.658 (4.083–10.856)
IGRA (+)/Cavity (+)/> 35 year	10/28 (35.7)	18/28 (64.3)		4.514 (1.869–10.901)
IGRA (+)/Cavity (+)/≤ 35 year	28/33 (84.8)	5/33 (15.2)		45.500 (16.054–128.955)

TB tuberculosis, BALF bronchoalveolar lavage fluid, IGRA interferon-γ release assays